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Objectives: To evaluate the major risk factors for 
adverse short and long term outcomes in patients with 
active native valve infective endocarditis needing car-
diac surgery and to validate the EuroSCORE II in our 
cohort of patients.
Methods: We retrospectively studied 149 patients who 
underwent native valve surgery for infective endocar-
ditis in June 2000 - May 2011 at our referral centre. 
Ninety-six patients met the inclusion criteria for the 
study: 29 aortic valve replacements (AVR), 27 mitral 
valve replacements (MVR), 28 aortic/mitral (double) 
valve replacements (DVR) and 12 mitral valve repairs 
(MV Repair).
Results: Mechanical valves were implanted in 68 patients 
(70.8%), bioprosthetic valves in 16 (16.7%) and mitral 
annuloplasty rings in 12 (12.5%). The Cox proportional 
hazard model showed that the most important risk 
factors for early 30-day mortality were: critical pre-
operative state, emergency surgery, EuroSCORE II 
>12%, low cardiac output state (LCOS), HIV positive 
status, preoperative embolic episodes, vegetation size 
>1cm and postoperative ventilation >24 hours. The 
EuroSCORE II underestimated early mortality for the 
entire cohort. The discriminatory ability was evaluated 
with the receiver operating characteristic (ROC) curve 
with an area under the curve of 0.796. The discrimi-
natory ability in the subgroup analysis showed that the 
AUROC curve was poorer for MVR (0.696), 0.837 for 
DVR and better for AVR group (0.92). 
Conclusions: The EuroSCORE II underestimated mor-
tality in the highest risk groups and overestimated 
mortality in the lowest risk groups. The discriminatory 
ability and model fi t were evaluated to be good and 
a EuroSCORE II >12% predicted a signifi cantly higher 
early and medium term mortality.  
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INTRODUCTION
Infective endocarditis was initially described in the early 16th 
century and only methodically reviewed after the 19th century 
when Osler made his contribution to the Royal College of 
Physicians in 1885.(1)
There has been little change in the mortality from infective 
endocarditis, despite the diagnostic and therapeutic advances 
made in the last 25 years. The current in-hospital mortality 
rate for patients with IE is 15% - 20%, with 1-year mortality 
approaching 40%. The morbidity associated with infective 
endocarditis includes: valvular incompetence, embolisation, 
cerebrovascular accidents and congestive heart failure which 
have influenced the surgical approaches to a great extent.(2) 
Infective endocarditis is a significant problem in sub-Saharan 
Africa and is related to a high prevalence of rheumatic heart 
disease among the young indigent population. Africa has the 
highest burden of rheumatic heart disease contributing 17% - 
43% of all heart disease.(3) The incidence of infective endocarditis 
in patients with rheumatic heart disease has not been clearly 
documented in literature. 
The microbiological profile of infective endocarditis is depend-
ent on patient risk factors and exposure. Coagulase Negative 
Staphylococci and Staphylococcus Aureus endocarditis have 
been shown to be associated with hospital acquired infections 
and streptococcal endocarditis with community acquired infec-
tions.(4) Early mortality has been associated with staphylococcal 
infections, vegetation size, embolic load and, most importantly, 
the immediate preoperative pathophysiologic state.(5) Studies 
have shown that there is little difference in the recurrence of 
infective endocarditis when comparing mechanical and bio-
prosthetic implants.(6) However, few studies have been done 
to show the role of mitral valve repair in patients with active 
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native valve endocarditis. The few studies show that the bene-
fit of repair over replacement for non-infective mitral valve 
disease also holds true for active native mitral valve endo-
carditis. In one study, mitral valve repair in active endocarditis 
has been shown to have a good overall survival and low 
reoperation rate, but few studies compare this with outcomes 
for mitral repair in fully treated endocarditis or mitral replace-
ment in active endocarditis.(7) 
In a cohort of 92 patients with active endocarditis from 
Tygerberg hospital, a fellow tertiary referral hospital in the 
Western Cape of South Africa, the majority of patients were 
young males with underlying rheumatic heart disease (76%). 
Intravenous drug use, HIV infection and degenerative heart 
disease were rare and 77% of patients were culture negative.(8) 
In a review of infective endocarditis with negative blood 
cultures, prevalence rates of culture negativity ranged from 
10% - 30% and even higher in some poorly developed countries 
due to prior antibiotic use, fastidious organisms and fungal 
infections. This poses a problem in the choice of antibiotic 
regimens for these patients. Negative blood cultures were 
shown to be associated with a higher rate of major adverse 
cardiac events postoperatively.(9)
HIV infection in Africa, unlike that in the developed world, has 
been a major health problem in the last 20 years. HIV infection 
has widely affected the general population, unlike in most 
industrialised nations where HIV has been commonly asso-
ciated with intravenous drug use and social instability. Studies 
have shown that the risk of infective endocarditis does not 
increase with HIV infection and marantic endocarditis has not 
been described in Africa.(10)
The therapeutic strategy for managing infective endocarditis 
lies in the identification of micro organisms and their antibiotic 
sensitivities with directed antibiotic treatment, echocardio-
graphic assessment and early surgical intervention. Despite this 
approach, infective endocarditis has a high mortality and risk of 
major adverse cardiac events.(11) In all patients with infective 
endocarditis, approximately 50% require surgical interven-
tion(12) and the predicted mortality can be assessed with a 
number of scoring systems. The European system for cardiac 
operative risk evaluation (EuroSCORE) was introduced in 
1999, and in 2011 the updated EuroSCORE II was introduced 
with better prediction of operative risk.(13) The applicability and 
validity of this scoring model in the South African setting has 
not been evaluated. 
The aim of our study is to determine the role of various risk 
factors in early and late mortality and in major adverse cardiac 
and cerebrovascular events (MACCE), as well as to validate 
the EuroSCORE II in predicting mortality in our cohort of 
patients undergoing surgical treatment for active native valve 
endocarditis. 
MATERIALS AND METHODS
Study population and data collection
We retrospectively studied all patients (n=149) who had 
undergone cardiac surgery for infective endocarditis in June 
2000 - May 2011 at our tertiary referral centre. The indications 
for surgery were elective in 73 (48.3%), urgent in 51 (34.2%) 
and emergent in 25 patients (16.8%). Native valve endocarditis 
was present in 123 patients (82.6%) and prosthetic valve endo-
carditis in 26 patients (17.3%). The patients’ clinical charac-
teristics, i.e. demographics, microbiology, predisposing cardiac 
conditions, symptoms, previous cardiac surgery, echocardio-
graphic parameters and operative techniques were recorded 
and postoperative morbidity and mortality were followed-up, 
analysed as per Table I. Active native valve endocarditis was 
seen in 100 patients (67.1%) and 29 had AVR, 27 had MVR, 28 
had DVR, 12 had MV repair, 3 had isolated tricuspid valve 
surgery and one had aortic valve repair. Ninety-six patients met 
the inclusion criteria for the study and were thus included in 
the analysis. Exclusion factors were: fully treated endocarditis 
(n=23), prosthetic endocarditis (n=26), isolated tricuspid valve 
surgery (n=3) and primary aortic valve repair (n=1).
Bacteriologic characteristics
The microbiological etiology of endocarditis in our patients is 
shown in Table I. The most frequent organisms isolated were 
Staphylococci in 28 patients, comprising approximately equal 
numbers of Staphylococcus Aureus and Coagulase-negative 
Staphylococci. Streptococci were isolated from 29 patients. 
Various gram-negative organisms, including some from the 
HACEK group, occurred in 15% and no organisms were seen, 
cultured or identified from blood, valve tissue, serology or PCR 
in 26% of patients. Preoperative blood cultures were negative 
in 47% of patients.
Predisposing conditions
The predisposing cardiac conditions associated with infective 
endocarditis are reported in Table I. The most common under-
lying cardiac condition was rheumatic heart disease in 84% of 
patients, which was either known on history preoperatively, 
identified intra-operatively or detected histologically. Rarer 
predispositions included: degenerative disease in 2%, calcific 
degeneration in 2%, congenital heart disease in 2%, previous 
infective endocarditis on normal valves in 1%, mitral prolapse 
in 1%, and pacemaker device infection in 1%. There was no 
known underlying heart disease in 7% of patients. It has also 
been noted that the prevalence of HIV infection in the entire 
surgical cohort of patients was 8%. The mean age of our cohort 
was 35.2 ± 14 years and 69% were males. The prevalence of 
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HIV infection in females was 20% and 3% in males but the rate 
was higher in those with a poorer socioeconomic status (33% 
vs. 11% respectively). 
Preoperative characteristics and the EuroSCORE II
The preoperative characteristics are recorded in Table I. 
Operative risk was evaluated by the EuroSCORE II using the 
online calculator provided by the EuroSCORE study group.(13) 
The patients were also assessed as being critically ill if they 
had the following: pulmonary oedema, mechanical ventilation, 
cardiogenic or septic shock or renal failure requiring dialysis. 
Emergency surgery was defined as occurring within 24 hours of 
presentation, urgent surgery defined between 24 - 48 hours 
of presentation and elective surgery thereafter. The variables 
included patient-related, cardiac-related and operation-related 
factors. 
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TABLE I: Demographic and clinical characteristics of patients with active left sided native valve infective endocarditis for the 












Age (years) 35.2 ± 14.0 42.8 ± 13.6 29.7 ± 11.0 33.5 ± 11.8 33.7 ± 18.6
Male 66 (69%) 24 (83%) 14 (52%) 21 (75%) 7 (58%)
BMI 20.9 ± 4.5 22.1±4.5 20.9 ± 5.6 20.2 ± 3.9 20.1 ± 2.9
LVEF (%) 61.5 ± 11.9 57.1 ± 11.5 64.6 ± 13.1 62.5 ± 11.4 62.8 ± 9.5
LVEDD (mm) 6.0 ± 1.0 6.4 ± 0.8 5.9 ± 0.9 6.1 ± 1.1 5.3 ± 0.8
NYHA III-IV 55 (57%) 19 (66%) 17 (57%) 16 (57%) 3 (25%)
Comorbidities
HIV positive 8 (8%) 2 (7%) 4 (15%) 2 (7%) 0
Dialysis 6 (6%) 3 (10%) 0 3 (11%) 0
Stroke 14 (15%) 1 (3%) 7 (26%) 3 (11%) 3 (25%)
Atrial fi brillation 10 (10%) 1 (3%) 4 (15%) 5 (18%) 0
Indications for surgery
Vegetation size >1cm 43 (45%) 11 (38%) 14 (52%) 13 (46%) 5 (42%)
CCF 79 (82%) 27 (93%) 23 (85%) 19 (68%) 10 (83%)
Failed medical therapy 83 (87%) 24 (83%) 23 (85%) 27 (96%) 9 (75%)
Embolic phenomena 38 (40%) 8 (28%) 15 (56%) 12 (43%) 3 (25%)
Preoperative state
Critical pre-op state 26 (27%) 8 (28%) 8 (30%) 9 (32%) 1 (8%)
Emergency 20 (21%) 6 (21%) 7 (26%) 6 (21%) 1 (8%)
Urgent 35 (36%) 14 (48%) 10 (37%) 10 (36%) 2 (17%)
Elective 39 (41%) 8 (28%) 10 (37%) 12 (43%) 9 (75%)
EuroSCORE II >12% 20 (21%) 4 (14%) 5 (19%) 10 (36%) 1 (8%)
Concomitant procedures
Tricuspid Annuloplasty 13 (14%) 1 (3%) 3 (11%) 7 (25%) 2 (17%)
CABG 1 (1%) 0 0 1 (4%) 0
Prosthesis material
Mechanical 68 (71%) 21 (72%) 23 (85%) 24 (86%) 0
Bioprosthesis 16 (17%) 8 (28%) 4 (15%) 4 (14%) 0
Pericardial patch 6 (6%) 3 (10%) 0 3 (11%) 0
Annuloplasty ring 12 (13%) 0 0 0 12 (100%)
Microbiologic profi le
Unidentifi ed 26 (27%) 8 (28%) 5 (19%) 12 (43%) 1 (8%)
Staphylococci 26 (27%) 7 (24%) 11 (41%) 5 (18%) 3 (25%)
Streptococci 27 (28%) 4 (14%) 10 (38%) 8 (29%) 5 (42%)
Gram negative 17 (18%) 10 (34%) 1 (4%) 3 (11%) 3 (25%)
AVR = Aortic valve replacement, MVR = Mitral valve replacement, DVR = Double valve replacement, MV = Mitral valve, BMI = Body mass index, 
LVEF = Left ventricular ejection fraction, LVEDD = Left ventricular end diastolic dimension, NYHA = New York Heart Association, HIV = Human immunodeficiency virus, 













Operative characteristics and surgical techniques
All surgical procedures were performed via a median ster-
notomy on cardiopulmonary bypass with systemic cooling to 
28 and 32 degrees Celsius in all cases. Myocardial protection 
was by antegrade cardioplegia with, or without, additional 
retrograde cold blood cardioplegia. Aortic valve exposure was 
through an oblique aortotomy and mitral valve exposure was 
either through the Waterstons groove or via a biatrial tran-
septal approach. 
Gross pathological findings were leaflet destruction, vegeta-
tions, intracardiac abscesses and fistulae. The affected valves 
and surrounding structures were debrided off all macroscop-
ically infected material after which repair or replacement was 
performed. 
The types of prosthetic material implanted were: mechanical 
valves, bioprosthetic valves, annuloplasty rings and bovine peri-
cardial patches for reconstruction of the aortic root. Con-
comitant procedures were: atrial fibrillation ablation (1%), 
coronary artery bypass surgery (1%) and tricuspid annulo-
plasty (13%).
Follow-up
The patients were traced through telephonic contact, email 
contact, friends and relatives, through their local clinic, prison 
system, local police and the South African National Health 
Laboratory Service (NHLS). Long term follow-up was com-
pleted in 98.6% of patients. Cause of death was determined 
through the records of forensic pathology examination, death 
certificates and clinical notes prior to death in those patients 
who had been in hospital. Out-of-hospital deaths were deter-
mined from feedback of patients’ relatives, death certificates in 
the patients’ folders and the South African Home Affairs death 
registry. In-hospital mortality and less than 90-day mortality 
was classified as early and >90-day mortality as late. For the 
purpose of evaluating the EuroSCORE II which predicts 30-day 
mortality, the early mortality category was further subdivided 
into ≤30-day mortality (Table III). In the reporting of death and 
MACCE, the guidelines for the reporting of mortality and mor-
bidity after cardiac valve intervention were followed.(14)  
The results of long term follow up were evaluated using: NYHA 
functional status, hospital readmissions, thromboembolic 
events, bleeding episodes, prosthetic endocarditis, arrhythmias 
and heart block, paravalvular leaks, reoperations and mortality. 
The dates of these events were determined and the time to 
events calculated from the time of operation. Categorical, or 
continuous, variables that were missing due to incomplete 
medical records were left blank in the data sheets and this was 
accounted for during analysis.
Statistical methods
In the analysis of the data, variables were systematically 
expressed with standard definitions. The continuous variables 
were presented as median (range) and mean ± standard devi-
ation in the manuscript, where appropriate. Categorical 
variables were expressed as percentages. The Kaplan-Meier 
analysis was used to present actuarial survival estimates and 
freedom from major adverse valve related or cardiac events. 
The Cox proportional hazard regression model was used to 
evaluate hazard ratios, for both short and long term outcomes, 
after adjusting for confounding factors. The primary endpoints 
included in the study were: early 30-day mortality, early 90-day 
mortality and late mortality (>90 days). The secondary end-
points were: early MACCE and late MACCE. Significant hazard 
ratios at 95% confidence interval were identified and tabulated. 
A p-value of <0.05 was considered to be statistically significant. 
The validity of the EuroSCORE II was evaluated by its good-
ness of fit and discriminatory capacity. The Hosmer-Lemeshow 
test assessed the goodness of fit by estimating a statistic from 
the difference between observed and expected values for 
mortality in 10 different risk groups. A p-value of >0.05 indicates 
that the EuroSCORE II fits the data well and thus accurately 
predicts mortality. The EuroSCORE II’s ability to discriminate 
was assessed by its capacity to distinguish between patients 
who had died within 30 days from those who had not. The 
area under the receiver operating characteristic (AUROC) 
curve was used to evaluate the discriminatory power of the 
EuroSCORE II in our cohort of patients and the treatment 
sub-groups. The area under the curve ranges from 0.5 (no 
power) to 1.0 (absolute discriminatory ability). A cut point of 
predicted operative mortality, at which the highest specificity 
and sensitivity coincided, was determined for the entire cohort 
and confirmed by a maximal Youden’s index. The entire cohort 
was divided into 2 groups, one above and the other equal to 
or below this cut point. The 2 groups were then compared with 
Kaplan Meier survival estimation and freedom from MACCE.
The entire cohort was also divided into DVR and non-DVR 
groups (single valve replacement and mitral valve repair) and 
their long term survival and freedom from MACCE were 
compared with Kaplan Meier curves. 
RESULTS
Surgical procedure and study population
The preoperative demographic and clinical characteristics of the 
96 included patients are summarised in Table I. Gross 
pathological findings were: vegetations in 76 patients (79%), 
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intra-cardiac abscess in 30 (31%), ventricular septal defect in 3 
(3%) whilst all had various degrees of leaflet damage. Mechanical 
valves were most commonly implanted (70.8%) and pericar-
dial patch reconstruction of the aortic root was only needed 
in 6 patients.
The cut point of the EuroSCORE II model was evaluated to be 
12% at which the sensitivity and specificity were maximal 
(Youden’s index), and 21% of the entire cohort of patients had 
a score >12%. At the 12% cut point, the sensitivity of the 
EuroSCORE II to predict 30-day operative mortality was 73%, 
specificity of 88% and the positive predictive value was 44%.
Aortic Valve Replacement (Table I)
Of those patients who had an AVR (n=29): the mean age was 
higher than the other sub-groups (42.8 ± 13.6 years) and the 
majority were males (86%). More than half the patients had a 
poor functional status (NYHA ≥III) and only 7% were HIV 
positive. Thirty eight percent of patients had vegetation >1cm 
and only 3% had a preoperative stroke. A pericardial patch 
repair of the debrided aortic root was undertaken in 10% of 
patients. The majority of patients (72%) had a mechanical valve 
implanted and 14% had a concomitant mitral annuloplasty ring. 
The mean EuroSCORE II was 5.8 ± 6.1% and 14% of patients 
had a EuroSCORE II >12%. Among the 8 patients who were 
in a critical preoperative state, 7 required an emergency opera-
tion. The commonest organisms isolated were staphylococci 
in 7 (24%) patients and streptococci in 4 (14%). 
Mitral Valve Replacement (Table I)
In those patients who had MVR (n=27), the male to female 
ratio was not significantly different and more than half were in 
a poor functional status (NYHA ≥III) This group had the highest 
HIV positive rate (15%) and 52% had vegetations >1cm with a 
preoperative stroke rate of 26%. The majority of patients (85%) 
had a mechanical valve implanted. The mean EuroSCORE II 
was 5.39 ± 6.16 and 19% of patients had a score >12%. Among 
the 8 patients who were in a critical preoperative state, 7 
required emergency surgery. The commonest organisms were 
again staphylococci (41%) and streptococci (38%). 
Aortic and Mitral Valve Replacement-DVR (Table I)
In patients with active native endocarditis who had DVR 
(n=28): the majority were males (71%) and more than half had 
an NYHA class ≥III. Most of the patients (86%) had mechanical 
valves implanted and 11% required a pericardial patch to 
reconstruct the aortic root. The mean EuroSCORE II was 10.6 
± 9.4 and 11 patients (39%) had a EuroSCORE II >12%. There 
were 9 patients (32%) who were in a critical pre-operative 
state, 6 of whom required emergency surgery (21%), and a 
further 10 (36%) patients needed urgent surgery. 
Mitral Valve Repair (Table I)
A total of 12 patients had isolated mitral valve repair for active 
native mitral valve endocarditis. The male to female ratio was 
not significantly different and only 25% were in NYHA 
class ≥III. None of the patients were HIV positive. The 
preoperative stroke rate was 25% and 42% had vegetations 
>1cm. The pathology found at surgery included: leaflet per-
foration in 67%, chordal rupture and prolapse in 83%, and all 
were assessed to have annular dilation intraoperatively and 
required annuloplasty to reduce the annular diameter. All the 
patients received Colvin-Galloway future band annuloplasty 
prosthesis, chordi were replaced with Goretex in 83% and 
1 patient required a pericardial patch augmentation of the 
posterior leaflet. The mean EuroSCORE II was 3.0 ± 3.9% and 
only 1 patient had a EuroSCORE II >12%. Only 1 patient 
required emergency surgery and was in a critical condition pre-
operatively. The commonest organism isolated was Strepto-
cocci in 42% of patients. 
Postoperative morbidity and early mortality
Table II shows the early and late postoperative outcomes of 
the 96 patients with active native valve endocarditis. Two 
patients (2%) died immediate postoperatively and a total of 14 
patients (15%) died early (90-day mortality). Postoperative ino-
tropic support was needed in 73% of patients and 5% of 
patients developed low cardiac output state of which 1 patient 
required IABP support. Postoperatively, 6% of patients under-
went re-exploration for tamponade or bleeding. 
Table III shows that the commonest causes of in-hospital 
30-day mortality were septic shock (4 patients) and stroke 
(4 patients), and the other 3 were due to cardiogenic shock 
(2 patients) and tamponade (1 patient). Two more patients 
died of septic shock within 60 days and 1 of cancer within 90 
days. The patient with cardiogenic shock developed a low 
cardiac output state after AVR: transesophageal echocardi-
ography showed possible valve dehiscence, after emergent 
relook and repair on bypass the patient died 2 hours post-
operatively in ICU due to cardiogenic shock. 
The intensive care duration of stay was more than 24 hours in 
all of patients who had valve replacement and survived in ICU, 
and the ventilation period was greater than 24 hours in more 
than two thirds in each subgroup. DVR had the highest early 
mortality with 7 patients (24%) dying within 90 days. 
Of the 6 patients who had reoperations: 3 were early (1 for 
cardiogenic shock due to suspected prosthetic endocarditis but 













endocarditis and the other iatrogenic native aortic regurgitation 
after MVR). The most common early MACCE after aortic valve 
replacement was heart block in 2 patients and reoperation in 
2 other patients. Relook for tamponade/bleeding occurred in 
3 patients post DVR (11%) and 3 patients post AVR (11%). 
The Cox proportional hazards model (Table IV) shows that the 
most significant hazard ratios for early 30-day mortality were: 
critical preoperative state, emergent surgery, EuroSCORE II 
>12%, HIV positive, LCOS, preoperative embolic episodes, 
vegetations >1cm, NYHA ≥III, and ventilation >24 hours. After 
adjusting for age, sex, DVR, HIV positive status and NYHA 
class; LCOS, preoperative embolic episodes and ventilation 
>24 hours were the most significant hazard ratios. When we 
evaluated early 90-day mortality, the most significant hazard 
ratios after adjusting for these risk factors were: critical pre-
operative state, EuroSCORE II >12%, LCOS, preoperative 
embolic episodes, and ventilation >24 hours. The most 












Inotropic support 70 (73%) 26 (90%) 21 (78%) 19 (68%) 4 (33%)
LCOS 5 (5%) 0 2 (7%) 3 (11%) 0
Dialysis 6 (6%) 3 (10%) 0 3 (11%) 0
Tamponade/Relook 6 (6%)  3 (10%) 0 3 (11%) 0
30-day mortality 11 (11%) 1 (3%) 4 (15%) 6 (21%) 0
90-day mortality 14 (15%) 2 (7%) 4 (15%) 7 (24%) 1 (8%)
ICU stay >24hrs 91 (95%) 29 (100%) 26 (96%) 26 (93%) 10 (83%)
Ventilation >24hrs 78 (81%) 26 (90%) 22 (81%) 20 (71%) 10 (83%)
Early MACE
Bleeding 3 (3%) 1 (3%) 0 1 (4%) 1 (8%)
Clotted valve 1 (1%) 0 0 1 (4%) 0
Embolic stroke 4 (4%) 1 (3%) 3 (11%) 0 0
Heart block 3 (3%) 2 (7%) 1 (4%) 0 0
Haemorrhagic stroke 2 (2%) 0 0 2 (7%) 0
Paravalvular leak 1 (1%) 0 0 1 (4%) 0
Repaired valve failure 1 (1%) 0 0 0 1 (8%)
Reoperation
Other valve failure 1 (1%) 0 1 (4%) 0 0
Paravalvular leak 2 (2%) 2 (7%) 0 0 0
Late MACE
Clotted valve 3 (3%) 1 (3%) 0 2 (7%) 0
Embolic stroke/endocarditis 1 (1%) 0 0 1 (4%) 0
Embolic stroke 1 (1%) 0 0 1 (4%) 0
Haemorrhagic stroke 2 (2%) 1 (3%) 1 (4%) 0 0
Paravalvular leak 1 (1%) 1 (3%) 0 0 0




2 (2%) 0 1 (4%) 1 (4%) 0
Embolic stroke/
bioprosthesis failed
1 (1%) 0 0 1 (4%) 0
>90-day all mortality 12 (13%) 3 (10%) 3 (11%) 6 (21%) 0
>90-day valve mortality 10 (10%) 2 (7%) 2 (7%) 6 (21%) 0
All-cause mortality 26 (27%) 5 (17%) 7 (26%) 13 (46%) 1 (8%)
Valve related mortality 23 (24%) 4 (14%) 6 (22%) 13 (46%) 0
AVR = Aortic valve replacement, MVR = Mitral valve replacement, DVR = Double valve replacement, MV = Mitral valve, LCOS = Low cardiac output state, 
ICU = Intensive care unit, MACE = Major adverse cardiac event.
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significant adjusted hazard ratios for early MACCE (Table IV) 
were: critical preoperative state, EuroSCORE II >12%, LCOS, 
pre-op embolic episodes, pre-op dialysis and NYHA ≥III.  
The EuroSCORE II had a Hosmer-Lemeshow statistic of 12.4 
(p-value=0.13) and an AUROC of 0.796. When the discrimi-
natory ability was evaluated within the subgroups, the AUROC 
curve was poorer for MVR (0.696), 0.837 for DVR, better for 
AVR (0.92) and not assessed for MV repair, as there were no 
early deaths (Table V). The EuroSCORE II underestimated 
mortality in the entire cohort as well as the subgroups, except 
in the AVR and MV repair groups, where the observed mortality 
was lower, or absent, respectively (Table V). 
Long term outcome, reoperation and major adverse 
cardiac events
A total of 98% of the patients were followed-up completely 
and 2 patients were lost to follow-up at 62 and 64 months after 
TABLE III: The causes of early and late mortality in the 












Cardiac tamponade 1 1 0
Cardiogenic shock 2 2 0




Septic Shock 4 6 0
Embolic CVA 2 2 4
Haemorrhagic CVA 2 2 2
Non valve related
Bowel Obstruction 0 0 1
Cancer 0 1 0
HIV related 0 0 1
CVA = Cerebrovascular accident, HIV = Human immunodeficiency virus.
TABLE IV: Cox proportional hazard analysis: The statistically significant risk factors for early mortality (30 day), early MACCE, late 
mortality and late MACCE (>90 day) in the entire cohort of patients, adjusted for age, sex, NYHA, DVR and HIV status.
N Person-time N events Event Rate/1 000 Adj. HR (95% CI)
Variable for Early mortality 30 Day
HIV positive
No 88 128 900 8 0.06 1.0 (ref)
Yes 8 4 571 3 0.66 5.4 (1.4 - 20.7)
LCOS No 91 133,400 6 0.05 1.0 (ref)
Yes 5 42 5 119.00 36.4 (6.5 - 203.7)
Pre-op emboli No 58 82,440 2 0.02 1.0 (ref)
Yes 38 50,989 9 0.18 10.2 (1.8 - 58.0)
Ventilation >24 hours No 76 115,900 4 0.03 1.0 (ref)
Yes 17 16,577 5 0.30 6.9 (1.4 - 33.4)
Variable for Early MACCE*
Critical Pre-op State
No 70 92,484 6 0.06 1.0 (ref)
Yes 26 23,956 12 0.50 3.5 (1.2 - 10.1)
EuroSCORE II >12
No 70 94,238 6 0.06 1.0 (ref)
Yes 26 22,202 12 0.54 4.4 (1.5 - 12.9)
LCOS
No 91 116,400 15 0.13 1.0 (ref)
Yes 5 42 3 71.43 6.1 (1.5 - 24.6)
Pre-op emboli
No 58 77,493 7 0.09 1.0 (ref)
Yes 38 38,947 11 0.28 3.1 (1.1 - 8.5)
Pre-op dialysis
No 90 115,900 13 0.11 1.0 (ref)
Yes 6 531 5 9.42 5.0 (1.5 - 17.1)
NYHA ≥III
No 41 55,681 1 0.02 1.0 (ref)
Yes 55 60,759 17 0.28 16.8 (2.2 - 128.3)
Variable for Late Mortality
HIV
No 88 128,900 10 0.04 1.0 (ref)
Yes 8 4571 2 0.11 6.6 (1.0 - 42.9)
DVR
No 68 106,300 6 0.06 1.0 (ref)
Yes 28 27,147 6 0.22 8.1 (1.9 - 34.0)
Variable for Late MACCE
DVR
No 68 104,900 6 0.06 1.0 (ref)
Yes 28 27,147 6 0.22 6.0 (1.6 - 22.2)
MACCE = Major adverse cardiac and cerebrovascular events, NYHA = New York Heart Association, EuroSCORE = European system for cardiac operative risk evaluation, 













TABLE V: Observed and predicted 30-day mortality of the combined and treatment sub-groups with the AUROC curve.
Average Predicted 30-day 
mortality EuroSCORE II 
(%)
Observed 30-day 
mortality % p-value AUROC
AVR (n=29) 5.8 3.4 0.54 0.92
MVR (n=27) 5.4 14.8 0.03 0.696
DVR (n=28) 10.6 21.4 0.06 0.837
MV repair (n=12) 3 0 0.54 -
Combined (n=96) 6.6 11.5 0.06 0.796
AUROC = Area under receiver operating characteristic, AVR = Aortic valve replacement, MVR = Mitral valve replacement, DVR = Double valve replacement, 
MV repair = Mitral valve repair.
surgery. After excluding 90-day early mortality (14 patients), 
the median follow-up was 51 months and ranged from 7 - 140 
months during which period 12 patients died. Kaplan-Meier 
survival analysis was used to estimate the actuarial survival at 
5 years (77.6% ± 4.6%) and 10 years (52.6% ± 15.9%) for 
the entire cohort of 96 patients. All-cause mortality after 90 
days was 13% and valve related mortality was 10%. The most 
common causes of >90 day valve related mortality were 
stroke (6%) and clotted valve (3%) and 1 patient died of pros-
thetic endocarditis (Table III). The 2 patients who died of non-
valve related causes were due to HIV related infection in 1 (11 
months) and bowel obstruction in the other (63 months). 
The 3 late reoperations were for prosthetic endocarditis (2 
patients at 59 and 100 months) and bioprosthetic mitral valve 
stenosis (1 patient at 58 months after DVR); and all 3 patients 
who had late reoperation died. Recurrence of endocarditis 
on the prosthetic valve occurred in 3 patients (3%) with 100% 
mortality and all were on mechanical valves (NS). 
The Cox proportional hazards model (Table IV) showed that 
the most significant adjusted hazard ratios for late mortality 
were: female sex, HIV positive status and patients who had 
DVR; and for late MACCE were: DVR and the use of peri-
cardial patch reconstruction of the aortic root. 
Figure 1A, shows the Kaplan Meier survival analysis of patients 
with a EuroSCORE II >12% vs. ≤12%. The higher risk group 
had a significantly lower early to midterm survival and similar 
late survival when compared to the lower risk group (55.0 ± 
11.1% vs. 94.7 ± 2.5% at 90 days; 55.0 ± 11.1% vs. 83.3 ± 4.7% 
at 5 years; and 45.8 ± 12.5 vs. 39.1 ± 27.8 at 10 years with 
p=0.0001).
Actuarial survival estimates of freedom from valve related mor-
tality determined for the 4 main treatment groups at 5 and 10 
years (AVR was 84.9 ± 7.1% and 84.9 ± 7.1%; for MVR was 
79.1 ± 8.6% and 39.6 ± 28.3%; for DVR was 59.3 ± 9.5% 
and 19.8 ± 16.5%; and no valve related mortalities in the 
MV repairs). A comparison of the long term survival of DVR vs. 
the rest of the patients (non-DVR group) shows that the 
former group had a significantly higher mortality and lower 
freedom from MACCE (Figure 1B: p=0.0002 and p=0.007, 
respectively).
DISCUSSION
Our retrospective study describes the early and long term 
outcomes of 4 main surgical options for active native valve 
endocarditis and the validity of the EuroSCORE II in the cohort 
of patients at a single centre. We have shown that the overall 
early 30-day mortality was high (11%) and the most significant 
risk factors were: LCOS, preoperative embolic episodes and 
ventilation >24 hours after adjusting for age, sex, NYHA class 
≥III, DVR and HIV status. The most significant risk factors for 
late mortality were: the female sex, HIV positive status and 
patients who had DVR (after adjusting for HIV status and 
female sex). In our cohort of patients, the prevalence of HIV 
infection in females (20%) was higher than the reported 
prevalence of HIV infection of 11% - 18% in this age group in 
the Western Cape population during our study period. There 
was a low prevalence of HIV infection of 3% in our male 
cohort compared to the reported prevalence of 6% - 8%.(15) 
The lower prevalence rate in males may be attributed to 
selection bias during the time of surgery, even though the 
clinical decision to operate a patient with infective endocarditis 
was not directly influenced by concomitant HIV infection. 
Other factors, beyond the scope of this study, may influence 
the prevalence rates seen. When we looked at the composite 
end point of MACCE, the most significant preoperative adjusted 
risk factors were: critical preoperative state, EuroSCORE II 
>12%, preoperative embolic episodes, preoperative dialysis 
and NYHA ≥III. The most important immediate postoperative 
risk factor for MACCE was low cardiac output state (LCOS). 
Within the AVR sub-group, preoperative stroke, critical physi-
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FIGURE 1A: Long term freedom from (A) Valve related mortality and (B) Major adverse cardiac events (MACCE) in patients with 










































Post-operative years Post-operative years
EuroSCORE ≤12%            EuroSCORE >12%
p-value=0.0001 90 days 5 years 10 years
EuroSCOREII 
≤12% (n=75)
Percent 94.7 ± 2.5 83.3 ± 4.7 39.1 ± 27.8
No. at risk 72 30 1
EuroSCOREII 
>12% (n=70)
Percent 55.0 ± 11.1 55.0 ± 11.1 45.8 ± 12.5
No. at risk 12 7 3
p-value=0.0002 90 days 5 years 10 years
EuroSCOREII 
≤12% (n=76)
Percent 97.1 ± 2.0 75.5 ± 5.9 29.8 ± 21.5
No. at risk 72 31 1
EuroSCOREII 
>12% (n=70)
Percent 61.5 ± 9.5 46.2 ± 9.8 31.7 ± 10.9
No. at risk 13 5 2
FIGURE 1B: Long term freedom from (A) Valve related death and (B) Major adverse cardiac events in patients who had double 
valve replacement (DVR) compared to those who had single valve replacements and mitral valve repair. DVR is shown to be a higher 










































Post-operative years Post-operative years
DVR            SVR/MV repair
p-value=0.0002 90 days 5 years 10 years
DVR 
(n=28)
Percent 75 ± 8.2 59.3 ± 9.6 19.8 ± 16.5
No. at risk 22 8 1
SVR/MV 
repair (n=68)
Percent 91.2 ± 3.4 85.0 ± 4.8 63.7 ± 18.8
No. at risk 62 29 3
p-value=0.0007 90 days 5 years 10 years
DVR 
(n=28)
Percent 85.7 ± 6.6 55.4 ± 9.7 18.5 ± 15.4
No. at risk 25 8 1
SVR/MV 
repair (n=68)
Percent 98.5 ± 1.5 72.2 ± 6.1 44.2 ± 14.1













ologic state and the use of pericardial patch (marker of exten-
sive root pathology) were significant risk factors for valve 
related mortality. In the MVR group the significant risk factors 
for valve related mortality were LCOS. And finally, in the DVR 
group, the significant risk factors were LCOS and the use of 
the pericardial patch. Our patients with mitral valve repairs had 
no valve related mortality and the significant risk factor for 
adverse events was prolonged ventilation >24 hours. The DVR 
group had a significantly higher early and late mortality and 
lower freedom from major adverse cardiac events (p=0.0002) 
than the other treatment groups. 
The EuroSCORE II underestimated 30-day mortality in the 
combined and sub-groups, except the AVR group and its 
discriminatory power was the least in the MVR group. We 
determined that at a cut-point of 12%, the EuroSCORE II 
had the highest sensitivity (73%) and specificity (88%) for the 
entire cohort with a positive predictive value of 44%. 
In a review by Anguera, et al., severe aortic or mitral valve 
regurgitation causing congestive cardiac failure is the most 
important indication for surgery, the most frequent cause of 
mortality and a significant risk factor for early mortality and 
morbidity.(16) In a study evaluating the risk factors for embolism 
and 6-month mortality in 216 patients with infective endo-
carditis, Hill, et al. showed that mobile vegetations, size >10mm 
were associated with new embolic episodes and the latter 
predicted 6-month mortality(17) which was a consistent finding 
in our study. When surgical management is the option for 
managing infective endocarditis, a thorough debridement and 
bioprosthetic or mechanical valve replacement has a low endo-
carditis recurrence risk.(18) There was no significant difference in 
rate of recurrent endocarditis between mechanical and bio-
prostheses in our patient cohort, although no endocarditis was 
reported on bio-prostheses. The current literature shows that 
there is no significant difference between the incidence of 
mechanical and bioprosthetic endocarditis.(6)
In a study of 78 patients operated for mitral endocarditis at a 
single centre in France by Iung, et al., 80% were amenable for 
repair. Repair in active endocarditis was associated with a 
higher rate of major adverse cardiac events but had equivalent 
survival to those with fully treated endocarditis.(19) Only 30% 
of our patients with mitral endocarditis were amenable for 
repair and they had no valve related mortality but 33% had 
major adverse cardiac events.
A retrospective study by Chu, et al., on 267 patients with 
infective endocarditis, found that critical physiological state, 
staphylococcal infection, diabetes mellitus and embolic events 
were independent predictors of in-hospital mortality.(20) In 
another study by Davids, et al., 383 patients having surgery for 
infective endocarditis had staphylococci as the most common 
organism. A critical preoperative state and staphylococcal 
infection were independent risk factors for operative mortality. 
In addition age, recurrent endocarditis and ventricular ejection 
fraction of less than 40% were independent predictors of all-
cause mortality.(21) Our study showed that a critical preopera-
tive state, but not staphylococcal infection, was associated 
with early mortality, and recurrent endocarditis was associated 
with reoperation and mortality in over 60%. 
In a long term outcome study of 346 patients between 1986 - 
2005, the 10- and 15-year survival after valve replacement 
surgery for patients with infective endocarditis without intra-
venous drug use was 56% and 42% respectively.(22) Our cohort 
had a similar 10-year survival at 52.6 ± 15.9. A review of 37 
patients with active infective endocarditis had mitral valve repair 
surgery and a 10-year survival and freedom from reoperation of 
80%.(7) This study showed that mitral valve repair could be 
achieved with good long term survival and low rate of reopera-
tion that was comparable to patients with no endocarditis and 
consistent with our findings. 
Most of the studies reviewing active native valve endocarditis 
had a heterogeneous cohort of patients with different treat-
ment modalities, and assessed outcomes of the overall group. 
Our study shows that the cohort consists of a heterogeneous 
group and analysing them, based on different treatment 
modalities, reveals that patients who had DVR had a significantly 
higher valve related mortality compared to the non-DVR treat-
ment groups (59.3 ± 9.5 vs. 78 ± 6.3 at 5 years p=0.009), 
probably related to the more extensive degree of infection. 
In a study evaluating the EuroSCORE II in 3 479 Chinese 
patients, the model gave a more accurate prediction for single 
valve (AUROC of 0.792) than multiple valve surgery (AUROC 
of 0.605) with respect to discriminatory ability and calibration. 
This was attributed to the lack of the incorporation of certain 
valve related risk factors such as left ventricular dimensions 
into the EuroSCORE II model.(23) In another study comparing 
the EuroSCORE II in a Turkish cohort of 428 patients, the 
model was shown to underestimate mortality risk for the 
entire cohort.(24) Our study cohort, though small, showed a 
similar pattern with the predicted mortality being underesti-
mated in the entire cohort but overestimated in the lower risk 
AVR and MV repair groups. In addition, the EuroSCORE II 
had a better discriminatory ability for early mortality in the 
AVR group than the other sub-groups in our study. In general, 
the EuroSCORE II had good discrimination and calibration for 
our entire cohort. Contrary to the results of our study, a recent 
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prospective validation of the EuroSCORE II in Argentina 
showed that it underestimated in-hospital mortality in the 
lowest risk cases but performed well in the higher risk patients. 
They attributed this to inadequate model behaviour and/or 
surgical care.(25) However, in our situation the EuroSCORE II 
overestimated operative mortality in the lower risk groups and 
underestimated mortality in the higher risk groups. This may be 
explained by good surgical performance in the lower risk 
groups and poor surgical performance in the higher risk groups. 
Study limitations
The major limitation of this study is the inherent bias related 
to the retrospective and observational nature of the study. 
Patient selection, indication and timing of surgery may also 
affect the findings related to referral patterns and duration of 
antibiotic therapy. Another limitation is the heterogeneity of 
the procedures undertaken and micro-organisms involved in 
the disease process. The small sample size also affects the 
assessment of the validity of the EuroSCORE II in our cohort of 
patients. Our cohort of patients is a high-risk category due to 
the underlying nature of the disease and this can have an 
influence on the underestimation of the predicted mortality by 
the EuroSCORE II.
CONCLUSIONS
We concluded that the most important risk factor for early 
outcome was LCOS, and for long term outcome it was DVR. 
The EuroSCORE II had a good discriminatory ability and cali-
bration, but generally underestimated mortality for the entire 
cohort of patients. Underestimation occurred particularly in the 
DVR and MVR groups, whereas, the EuroSCORE II over-
estimated mortality in the AVR and MV repair groups. This may 
be due to poor surgical performance in the higher risk patients 
and good surgical performance in the lower risk patients, 
respectively. When evaluating the EuroSCORE II at a cut point 
of 12%, it was evident that the higher risk group (>12%) had a 
significantly higher early and medium term mortality than the 
lower risk group (≤12%). 
We will, however, need to evaluate a larger cohort of patients 
with other underlying cardiac conditions in order to make a 
more robust validation of the EuroSCORE II model in the 
South African context.
Conflict of interest: none declared.    
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